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Abstract 
This retrospective study of prospectively collected data examines the effect of 
prednisolone therapy on raised uterine Natural Killer cell (uNK) concentrations and 
pregnancy outcomes in women with recurrent miscarriage (RM) and recurrent 
implantation failure (RIF) after IVF/ICSI treatment. 136 women diagnosed with RRF 
who had a timed midluteal endometrial biopsy taken for uNK cell analysis were 
included. Women with high uNK cell concentrations (n=45) were treated with 
prednisolone (10mg/day) for one month, after which a second biopsy was taken for 
repeat uNK cell analysis. Women for whom prednisolone caused a decrease in uNK 
cell concentrations continued on prednisolone until 12 weeks of pregnancy. 
Pregnancy outcomes (live birth, miscarriage and implantation rates) and pregnancy 
complications were compared for women who received prednisolone and those who 
did not. Results showed that the prevalence of high uNK cells was 33.1%. 
Prednisolone significantly decreased the uNK cell concentration (P<0.001), however 
reduction to normal limits was achieved in only 48.3% of patients. There was no 
difference in any of the pregnancy outcomes or complications between women who 
had received prednisolone and those who had not. In conclusion, this study showed 
a relatively high prevalence of raised uNK cells in women with recurrent reproductive 
failure and confirmed the effect of prednisolone on reducing uNK cell concentrations. 
We found however no evidence for a significant beneficial effect for prednisolone 
therapy on pregnancy outcomes. Until the results of an adequately powered RCT 
become available however, these findings should be considered preliminary  
 
Key Words Endometrium; uNK cells; Prednisolone; Recurrent Miscarriage; 
Recurrent Implantation Failure 
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Introduction 
The endometrium consists of a population of natural killer cells distinct from 
peripheral blood cells. The majority (90%) of peripheral blood natural killer cells 
(pNK) are CD56dimCD16+ and a minority (10%) are CD56brightCD16-, whilst in the 
endometrium the majority (90%) of cells are CD56brightCD16- and a minority (10%) 
are CD56dim CD16+ (Bulmer et al. 1991). These cell populations also differ in function 
with the endometrial CD56brightCD16- population showing increased cytokine 
production and decreased cytotoxicity, compared to the CD56dimCD16+ peripheral 
blood cells (Saito et al. 1993, Deniz et al. 1994, Koopman et al. 2003).  
The numbers of endometrial NK (uNK) cells increase rapidly during the mid-
secretory phase and remain high during the first trimester of pregnancy, suggesting 
that they play a role in embryo implantation. Their presence in close proximity to 
uterine blood vessels and the invading trophoblast suggest that they may play a role 
in spiral artery remodeling or trophoblast cell growth or function (Smith et al. 2009, 
Lash et al. 2010). 
High uNK cell concentrations have been found in patients with reproductive failure 
including recurrent miscarriage (Quenby et al. 2005) and repeated implantation 
failure (RIF) after in vitro fertilization treatment (IVF) (Tuckerman et al. 2010), 
although other studies in women with RIF have suggested no change in NK cell 
concentrations in the endometrium of women with RIF (Matteo et al. 2007). 
Differences in findings may be because the definition of a "high" uNK cell count 
differs between research groups; even within the United Kingdom two groups have 
initially defined high as either greater than 5% (Quenby et al. 2005) or greater than 
13% (Tuckerman et al. 2010). These differences in findings may be due to 
differences in the methods used to count uNK cell numbers and illustrate the 
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importance of adopting a standardized approach to cell counting in future studies 
(Lash et al. 2016).  
RRF: Recurrent reproductive failure 
RM: Recurrent miscarriage 
RIF: Recurrent implantation failure 
NK cells: Natural Killer cells 
IVF: In vitro fertilization 
 
Despite no clear understanding of the role that uNK cells may play in pregnancy 
outcomes, there are increasing requests from women with reproductive failure to  
undergo an endometrial NK cell count test and many centers are indeed offering this 
test. Furthermore there is a difference of opinion regarding a suitable treatment for 
women with "high" uNK cells, but many centers use prednisolone treatment (Laird et 
al. 2016). Prednisolone treatment is based solely on two small sample sized reports 
(Quenby et al. 2003, Quenby et al. 2005). In these studies, a repeat biopsy was not 
taken after prednisolone therapy, and therefore it is not known whether the 
prednisolone therapy resulted in a decrease in uNK cells or not. Despite this clear 
deficiency of the evidence, testing and treatment for raised uNK concentrations 
seems in many cases to have been rushed into clinical practice.  
The main aim of the current study is to effect of prednisolone on raised uNK cells 
concentrations in a well selected group of women with recurrent early reproductive 
failure and to investigate the effect of prednisolone treatment on uNK cell 
concentrations and pregnancy outcomes. As far as we are aware it is the first to 
examine both the effect of prednisolone on NK cell concentrations as well as 
pregnancy outcomes.  
Materials and Methods 
Patients 
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This was a retrospective analysis of prospectively collected data from a consecutive 
series of 164 women who had an endometrial biopsy between the 22nd June 2010 
and the 22nd May 2017, to test for uNK cells at the Jessop Wing, Royal Hallamshire 
Hospital, Sheffield, United Kingdom. The study examines data obtained from women 
undergoing investigations and treatment for raised uNK cells based on our Unit’s 
established protocol (Figure 1). 
Patients were included in the analysis if they had a diagnosis of recurrent 
miscarriage (RM) defined as having three or more consecutive pregnancy losses 
before 24 weeks gestation (Stirrat 1990) or RIF as defined by the failure to achieve a 
clinical pregnancy after the transfer of at least two embryos in a minimum of two 
fresh or frozen cycles. All patients underwent investigations including: thrombophilia 
screening, karyotyping, thyroid function tests and antibodies, androgen profile, 
gonadotrophins, ultrasonography and hysterosalpingography (Metwally et al. 2014). 
The study was approved by the University of Sheffield Ethics Application System. 
Tissue sampling and uNK cell analysis 
An endometrial biopsy sample was obtained using a Pipelle sampler on days LH + 6-
9 of the cycle according to the LH surge, which was measured by a urine ovulation 
test. The technique for sample preparation has been previously described by our 
group (Tuckerman et al. 2007). 
Cells were counted by one operator who assessed 10 x400 fields. The technique of 
counting uNK cells changed in July 2015. Prior to that date, fields of view were 
chosen at random throughout the tissue section. After July 2015, images were only 
chosen for analysis if adjacent to the luminal edge and a minimum of 3800 total 
stromal cells were counted. Counting the number of nuclei determined the number of 
total stromal cells. Counting the positively stained cells determined the number of 
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uNK cells. Data was expressed as the percentage of CD56+ uNK cells as a total of 
stromal cells.  
Definition of high uNK cell.  Prior to July 2015 (n=106) raised uNK was defined as a 
concentration of >13.9% (Tuckerman et al. 2007). The definition of raised uNK cells 
was redefined as more than 5% in July 2015 (n=30) with the change in our technique 
of measurement after comparison of methodology across a number of centers (Lash 
et al. 2016).  
Prednisolone Administration 
Patients with high uNK cells were offered 10 mg of prednisolone daily starting from 
the first day of the menstrual cycle. Nine patients with high uNK cells did not receive 
treatment due to the fact that even though, their uNK cells had been measured with 
the new technique, the new cut off limit for uNK had not yet been introduced and 
hence under the old classification system, they were considered to have normal uNK 
cells and hence not treated. Even though this group was not the result of a 
randomization process, they did provide an opportunity for comparison with those 
who had been treated. Prednisolone was continued until the biopsy was repeated 
again at LH +7-9 and was then gradually stopped while results were awaited.  
If the uNK count had dropped to within normal range, patients where prescribed 
prednisolone 10 mg when pregnant until 12 weeks gestation.  Those where the 
repeat biopsy did not show normalization of uNK cell concentrations, were 
prescribed a higher dose of 20 mg when pregnant, again until 12 weeks gestation. 
On discontinuation, the dose of prednisolone was always tapered gradually.  
Outcome measures  
a.  Primary: The effect of prednisolone on the uNK concentrations in 
women with raised uNK cells concentrations.  
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b. Secondary:  
i. 1- Prevalence of high uNK cell concentrations in women with 
recurrent reproductive failure  
ii. 2- The effect of prednisolone on pregnancy outcomes in women 
with raised uNK cells concentrations.. 
Pregnancy outcomes are defined as follows: 
a. Live birth rate (LBR) - calculated as the ratio between the number of 
patients achieving a live birth and the total number of patients. 
b. Miscarriage rate (MR) - calculated as the ratio between the number of 
miscarriages (confirmed pregnancies lost <24 weeks of gestation) and 
the total number of patients. 
c. Implantation failure rate (IFR) - calculated as the ratio between the 
number of cycles that ended in implantation failure and the number of 
women who underwent an embryo transfer (ET). 
d. Pregnancy complications 
I. 1- Antepartum hemorrhage (APH): vaginal bleeding from 
24 weeks gestation prior to birth of the baby 
II. 2- Gestational Diabetes: hyperglycemia first diagnosed in 
pregnancy according to the WHO criteria; fasting venous 
plasma glucose level >9mmol/L or a two hours level of >11 
mmol/L after ingestion of 75 g of oral glucose.  
III. 3- Pregnancy induced hypertension (PIH): diastolic blood 
pressure of >90mmHg on two consecutive occasions taken 
at least four hours apart diagnosed for the first time after 20 
weeks gestation  
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IV. 4- Emergency caesarean-section rate  
V. 5- Preterm labor (PTL), the number of babies born before 
37 weeks  
VI. 6- Intrapartum fetal distress: a pathological heart trace 
pattern seen during continuous fetal monitoring  
VII. 7- Small for gestational age (SGA): fetal growth less than 
two standard deviations below the mean for gestational age 
according to growth and development record charts  
VIII. admission to special care baby unit (SCBU)  
IX. 8- Stillbirth rate (number of babies born after 24 completed 
weeks of gestation without signs of life  
X. 9- Neonatal death rate (death of a baby within 28 days 
following birth) 
Statistical Analysis 
The normality in the distribution of data was established using a Kolmogorov-
Smirnov test. Data were expressed as mean (±SD), median (range) and 
percentages as appropriate. For comparison between two independent groups an 
independent t test or a Mann Whitney test was performed as appropriate. A chi 
square test was used to compare proportions. A Pearson/Spearman correlation was 
used as appropriate to investigate the relationship between uNK cell concentrations 
and variables. For comparison between uNK cell concentrations before and after 
treatment a Wilcoxon test was performed. Logistic regression analysis was used to 
examine the relationship between uNK classification (normal or treated) and other 
factors, which could influence the chance of having a live birth. These included: 
maternal age, gravidity, parity, infertility duration, time to pregnancy/cycle, early 
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cleavage/blastocyst transfer and single/multiple embryo transfer. Statistical 
significance was defined as P <0.05, analysis was performed using the Statistical 
Package for Social Sciences version 22 (SPSS, Inc., Chicago, IL). 
Results 
Demographics 
164 patients underwent a biopsy. Tissue processing was not possible for three 
biopsies. 16 patients were lost to follow-up. Data from one patient could not be 
included as she was participating in a separate interventional study. Eight patients 
were undergoing other forms of assisted conception treatment and were excluded in 
order to reduce heterogeneity of the population. Therefore, 136 patients were 
included in the analysis (108 with RIF and 28 with RM). 
The demographics for patients with high and normal uNK cell concentrations are 
shown in Table 1. 
A total of 45 women (33.1%) had high uNK cells [9/28 (32%) In the RM group and 
39/108 (36%) in the RIF group. For biopsies taken before July 2015 the median 
(range) uNK concentration was 9.0% (0.4%-48.2%) for the RIF group and 7.6% 
(1.5%-31.5%) for the RM group.  
After our change of methodology in July 2015 as described above, the median 
(range) uNK cell concentration was 5.5% (0.5%-17.7%) for the RIF group and 2.3% 
(2%-3.4%) for the RM group.  
There was no significant correlation between baseline uNK concentration and age, 
body mass index (BMI), duration of infertility, parity, gravidity, number of 
miscarriages or number of failed cycles. There was also no difference in any of the 
described demographics between the normal and high group. 
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There was also no significant association between a high uNK % and the type of 
miscarriage (primary or secondary), type of infertility or diagnosis (RM or RIF).  
The cause of the infertility in each group is shown in Table 2. There were 
significantly fewer patients with tubal factor infertility in women with normal uNK cells 
compared to those with high uNK cells (P=0.016). There were significantly more 
patients with endometriosis in women with normal uNK cell numbers compared to 
those with high uNK cell numbers (P=0.021) and there were no patients with both 
high uNK cells and endometriosis. 
The effect of Prednisolone treatment on uNK cell concentrations 
Of the patients with high uNK cells (n=45), 36 (80%) were prescribed prednisolone. 
A repeat biopsy for uNK cell concentration was obtained on day LH+7-9 in a 
subsequent cycle for 29 (80.4%) of these patients. The repeat biopsy showed that 
uNK cell concentrations significantly decreased after treatment with prednisolone 
(P<0.001) (Figure 2). In 14 (48.3%) patients uNK cell concentrations returned to the 
normal range and were classified as ‘responders’. In 15 (51.7%) patients uNK cell 
numbers did not return to the normal range and were classified as ‘non-responders. 
There were significantly more RM patients (P=0.011) in the responder group (Table 
3). There was no significant difference in the etiology of the infertility in women who 
responded to prednisolone and those who did not. 
The effect of prednisolone on pregnancy outcomes    
There was no significant difference in any of the pregnancy outcomes in women with 
low and high uNK cells regardless of prednisolone treatment. In the subgroup of 
women with high uNK cells there was also no difference on any of the outcomes 
whether prednisolone was used or not. Similar results were obtained when 
considering the RIF and the RM groups of women separately.  
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The relationship between uNK cell concentration before and after treatment with 10 
mg of prednisolone and the subsequent achievement of a live birth whilst remaining 
on treatment with prednisolone is shown in Figure 3. The uNK cell concentration 
before or after treatment was not predictive of a live birth nor was the drop in uNK 
cell concentration as a result of treatment. When comparing those who responded to 
one month of 10mg of prednisolone treatment and those that did not, there were also 
no significant difference in LBR, MR and IFR.  
The effect of prednisolone pregnancy complications  
There was no significant difference in the incidence of pregnancy complications 
between women who received prednisolone and those who had not (Table 4). Of the 
women in the treated group on 20 mg of prednisolone (n=2), only one baby was 
SGA. 
Discussion 
Despite the lack of sufficient studies regarding the effect of raised uNK cells on 
pregnancy outcomes uNK cell testing and treatment with prednisolone has become 
common practice. The first and foremost finding of this study was a relatively high 
prevalence of high uNK cell concentrations of 33%. Although a control group was not 
included in this study we used reports from previous studies to define a "high cell 
concentration". Prior to 2015 this was based on the analysis of Tuckerman et al, 
2007   where 13.9% was shown to be the highest value in a small cohort of fertile 
control patients. After 2015 we reduced this to 5% as we had aligned our counting 
method to that of others including Quenby et al, 2005 who had previously shown that 
5% represented the 75th percentile in fertile control women. This has been 
confirmed more recently by a further study which showed that the 95th percentile for 
uNK cells in a cohort of 84 control fertile women was 4.5% (Chen et al. 2017). The 
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incidence of 33% is higher than the incidence of other established causes for 
recurrent early pregnancy loss that are routinely tested for. For example, 
antiphospholipid syndrome has a prevalence of around 15% and uterine 
malformations have a prevalence of 1.8%-37.6% (RCOG 2011). If the clinical 
significance of uNK cells testing is confirmed, then recommendations for routine 
testing will need to be considered. However, at present, the evidence is insufficient 
to make such a recommendation. 
Regarding possible confounding factors, we found a significant association between 
the presence of tubal factor infertility and high uNK cells. CD56(+) NK cells have 
been found to be present in small numbers within the normal fallopian tube 
(Ardighieri et al. 2014). Although we do not have details regarding specific tubal 
pathology a proportion could be due to hydrosalpinges (Al Subhi et al. 2013)  which 
are known to be associated with poor reproductive outcomes.  We hypothesize that 
this increase in uNK may be related to an increase in tubal NK cells or as a response 
to an endometrial inflammatory reaction induced by hydrosalpinges or other 
inflammatory tubal conditions.  
Interestingly endometriosis, another condition which may also be associated with an 
inflammatory response, was conversely not found to be associated with an increased 
uNK cell concentration. Although this may be a chance finding, it is known that 
defective cytotoxicity of NK cells in the peritoneal space can lead to endometriosis, 
through poor tissue clearance of ectopic endometrial tissue (Thiruchelvam et al. 
2015). Although rather speculative, it may be that raised uNK cells may be 
associated with raised peritoneal NK cells that could promote successful clearance 
of ectopic endometrial tissue preventing endometriosis. 
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Secondly, we found a significant drop in uNK after prednisolone treatment albeit with 
a lower dose than that used previously (i.e. 10mg) (Quenby et al. 2003). However, 
this drop only reached normal range in 48.3% of patients. A recent paper, which 
investigated the effect of prednisolone treatment on a variety of immunological 
markers also showed that only 54% of their cohort responded to treatment (Ledee et 
al. 2018). There is limited information available about the reproducibility of 
endometrial markers between different cycles in the same women. The 
reproducibility of uNK cell concentration in paired endometrial samples from two 
different cycles in a small group of women suggested that the diagnosis of high cell 
counts would have changed in 30% of women (Mariee et al. 2012) and this variability 
may have affected the observed reduction in uNK cell concentrations in the second 
biopsy. The mechanism by which prednisolone reduces uNK cell numbers is not 
clearly understood. However, uNK cells have been shown to express glucocorticoid 
receptors (Henderson et al. 2003) and therefore a direct interaction between the 
steroid and the cells is possible. The longevity of the effect of prednisolone treatment 
on uNK cell concentrations is unknown and further work is needed to determine this. 
Despite the drop in uNK concentrations we found no evidence for improvement in 
pregnancy outcomes with prednisolone treatment. 
Other studies have explored the potential benefits of prednisolone treatment in 
women with high peripheral blood NK activity and found improvements in pregnancy 
outcomes (Ogasawara and Aoki 2000, Ubaldi et al. 2002). However, the clinical 
relevance of these findings is uncertain as the relationship between uNK0 and pNK 
cells is not clear (Laird et al. 2011). It remains to be seen if the use of a 20-mg dose 
would have resulted in improved outcomes. A large well powered RCT is therefore 
needed. 
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Until further evidence is available however it is reassuring that we found no evidence 
for an adverse effect on pregnancy. Prednisolone is assumed to have effect on the 
fetus as 90% is metabolized by the placenta(Addison et al. 1993). However other 
studies have suggested that administration may increase the likelihood of 
miscarriage and pre-term birth or growth restriction (Quenby et al. 2003, Gur et al. 
2004, Robertson et al. 2016). In our study, there was only one case (9.1%) of a baby 
born that was with IUGR. 
Limitations of the study 
This is a cohort study that lacks the strengths of an RCT however so far evidence 
from RCT’s is lacking. There has been one RCT addressing the use of prednisolone 
but was mainly a feasibility study and therefore underpowered to give an 
answer(Tang et al. 2013). Our study also included a number of patients registered in 
other hospitals (9.8%) where we could not examine their pregnancy outcomes and a 
number of women had unknown pregnancy outcome (22.2%). Furthermore as this is 
a retrospective study where no power calculation had been performed it is possible 
that the study was underpowered to show a clear effect. The data generated from 
this study however could form the basis for a sample size calculation in future 
prospective studies.  
Secondly, a potential confounding variable is that of the possible therapeutic effect of 
the endometrial biopsy which has been reported to improve pregnancy rates in 
women with recurrent implantation failure after IVF (Zhou et al. 2008, Karimzade et 
al. 2010). It is possible that the procedure improved implantation rates in both treated 
and non-treated groups, which diluted the effect of prednisolone treatment and made 
it more difficult to detect a significant effect.  
15 
 
  
The non-treatment group also included some women who had received a course of 
prednisolone that was later discontinued after demonstrating a lack of significant 
drop in uNK cell concentrations. It is possible that this short course of steroids did to 
an extent affect uNK cell activity thus influencing pregnancy outcomes in the non-
treatment group and diluting any significant difference between the groups. A pure 
placebo group with no intervention is therefore necessary, again this is best 
achieved through well designed RCT. 
We also included women who were over 40. This is not ideal when analyzing 
pregnancy outcomes and maternal and fetal complications, as women over 40 have 
worse fertility and obstetric outcomes (Ziadeh and Yahaya 2001, Malizia et al. 2009). 
However, our analysis did show that in this particular study age was not an important 
predictor of pregnancy outcome and our previous study showed no relationship 
between number of CD56+ cells and age (Tuckerman et al. 2007). Due to the above 
factors and particularly the absence of a control group, the findings of this study 
should be considered preliminary.  
Conclusions 
This study demonstrates a relatively high prevalence of high uNK concentrations in 
women with RRF. The study did not demonstrate any beneficial effect for 
prednisolone at on pregnancy outcomes. Therefore, at present there is no evidence 
to support treating women with raised uNK cell concentrations.   Until the findings of 
a larger randomized controlled study become available the results of this study 
should be considered preliminary. 
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Table 1. Demographics of women with normal and high uNK cell numbers.  
Demographic Normal (n=91) High (n=45) P value 
Age (SD) 35.9 (4.5) 36.0 (4.2) 0.881 
BMI (kg/m
2
) 23.8 (3.3) 24.1 (4.4) 0.621 
Gravidity  
median (range) 
1 (0-8) 1 (0-9) 0.306 
Parity  
median (range) 
0 (0-1) 0 (0-2) 0.802 
Duration of Infertility 
median (range) 
96.0 (31.0-104.0) 50.0 (33.0-60.0) 0.440 
RM n (%)  16 (17.6)  6 (13.3) 0.510 
RIF n (%) 72 (79.1) 36 (80) 0.905 
Women with both RIF 
and RM n (%) 
3 (3.3) 3 (6.7) 0.368 
Consecutive 
miscarriages  
median (range) 
4 (3-6) 4 (3-7) 1.0 
Failed cycles  
median (range) 
3 (2-7) 3 (2-6) 0.970 
Embryos transferred 
median (range) 
5 (2-13) 5 (2-10) 0.667 
 
Table 2. Etiology of infertility in women with normal and high uNK cell concentrations 
Etiology Normal (n=91) High (n=45) P value 
Unexplained n (%)  35 (38.5)  13 (28.9) 0.272 
Uterine n (%)  1 (1.1) 1 (2.2) 0.609 
Tubal n (%)  7 (7.7) 10 (22.2) 0.016* 
Mixed n (%)  15 (16.5) 9 (20) 0.612 
Anovulation n (%)  7 (7.7) 5 (11.1) 0.825 
Male factor n (%)  14 (15.4) 7 (15.6) 0.975 
Endometriosis n (%)  10 (11.0)  0 (0.0) 0.021* 
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Table 3. Demographics of women who responded to prednisolone treatment and those 
who did not. 
Demographic Non-Responders 
(n=15) 
Responders* 
(n=14) 
P value 
Age (y) 35.2 (3.3) 35.9 (5.0) 0.646 
BMI (kg/m
2
) 23.7 (3.8) 25.1 (5.9) 0.448 
Time between initial 
and second biopsy 
(days) 
57 (29-270) 56 (36-105) 0.959 
Duration of 
infertility (months) 
60.0 (22.0-180.0) 50.0 (15-204) 0.356 
RM n (%) 0 (0.0) 5 (35.7) 0.011* 
RIF n (%) 13 (86.7) 8 (57.1) 0.075 
Both RM and RIF 
 n (%) 
2 (13.3) 1 (7.1) 0.585 
Parity  
n (range) 
0 (0-1) 0 (0-2) 0.949 
Gravidity  
n (range) 
1 (0-5) 2.5 (0-7) 0.146 
Failed cycles  
n (range) 
3 (2-6) 3.5 (2-6) 0.821 
 
 Responders as defined by a drop in uNK concentrations to within normal range 
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Table 4 Fetal complications in the babies born to mothers who had received 
prednisolone and those who had not. The no prednisolone group consisted of women 
with both high and normal uNK cells. 
 No prednisolone 
(n=26) 
Prednisolone(n=11) P 
value 
Birth weight (gm) 3110.0  
(703-5441) 
3424.0  
(1895.0-4224.0) 
0.603 
Gestation (weeks) 39.0 (26.9-41.7) 39.7 (32.9-41.9) 0.603 
Neonatal complication* 
rate n (%) 
Admission to SCBU/ITU n 
SGA n 
8 (30.8) 
 
8 
1 
4 (36.4) 
 
3 
1 
0.740 
* includes SGA, admission to SCBU/ITU, neonatal death 
Note: there were 3 multiple births in the no prednisolone group, thus n=26 rather than n=23 
 
Legends to Figures 
Figure 1. Flow chart to show the treatment protocol for women suffering with 
repeated reproductive failure and high uNK cells. 
Figure 2. uNK cell number before and after treatment with prednisolone. Women 
with ‘high’ uNK cells were prescribed daily 10 mg of prednisolone for one month 
before a repeat biopsy was taken to measure the resulting uNK cell number *P<0.05. 
uNK cells were counted according to our original methodology in all samples. 
Figure 3. The relationship between uNK% before and after treatment and the 
subsequent pregnancy outcome. Figure shows the initial uNK cell number before 
treatment and the uNK cell number after one month of 10 mg of prednisolone 
treatment for each patient. Patients were then prescribed 10mg or 20 mg of 
prednisolone for their subsequent ART treatment or whilst conceiving naturally. uNK 
cells were counted according to our original methodology in all samples 
 
